Association between Cannabinoid CB1 Receptor Expression and Akt Signalling in Prostate Cancer

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Cipriano, Mariateresa ^a   Häggström, Jenny ^b   Hammarsten, Peter ^a   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR; PROTEIN KINASE B; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KI 67 ANTIGEN; PHOSPHOPROTEIN;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SPECIFIC SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; AGED; CANCER GRADING; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE; PROSTATE TUMOR; PROTEIN PROCESSING; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; PHOSPHOPROTEINS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84878758138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065798     Document Type: Article

References (51)

1. Freimuth N, Ramer R, Hinz B, (2010) Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332: 336-344.
2. Fowler CJ, Gustafsson SB, Chung SC, Persson E, Jacobsson SOP, et al. (2010) Targeting the endocannabinoid system for the treatment of cancer- a practical view. Curr Top Med Chem 10: 814-827.
3. Díaz-Laviada I, (2011) The endocannabinoid system in prostate cancer. Nat Rev Urol 8: 553-561.
4. Guindon J, Hohmann AG, (2011) The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463.
5. Velasco G, Sanchez C, Guzmán M, (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12: 436-444.
6. Ruiz-Llorente L, Sánchez M, Carmena M, Prieto J, Sánchez-Chapado M, et al. (2003) Expression of functionally active cannabinoid receptor CB1 in the human prostate gland. Prostate 54: 95-102.
7. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, et al. (2000) Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. 2000; 141: 118-126.
8. Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart J-P, (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56: 1-12.
9. Sánchez M, Sánchez A, Ruiz-Llorente L, Díaz-Laviada I, (2003) Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Letts 555: 561-566.
10. Sánchez M, Ruiz-Llorente L, Sánchez A, Díaz-Laviada I, (2003) Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15: 851-859.
11. Sarfaraz S, Afaq F, Adhami V, Mukhtar H, (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641.
12. Sarfaraz S, Afaq F, Adhami V, Malik A, Mukhtar H, (2006) Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell arrest. J Biol Chem 281: 39480-39491.
13. Olea-Herrero N, Vara D, Malagarie-Cazenave S, Díaz-Laviada I, (2009) Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br J Cancer 101: 940-950.
14. Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB, (2011) Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat 94: 34-43.
15. Ruiz L, Miguel A, Díaz-Laviada I, (1999) Δ9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Letts 458: 400-404.
16. Sreevalsan S, Joseph S, Jutooru I, Chadalapaka G, Safe SH, (2011) Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res 31: 3799-3807.
17. Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, et al. (2012) Cannabinoid Receptor Type 1 (CB1) Activation Inhibits Small GTPase RhoA Activity and Regulates Motility of Prostate Carcinoma Cells. Endocrinology 153: 29-41.
18. Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, et al. (1994) 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 8826-8830.
19. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, et al. (2011) Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 18: 846-856.
20. Endsley M, Thill R, Choudhry I, Williams C, Kajdacsy-Balla A, et al. (2008) Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123: 1318-1326.
21. Pacher P, Bátkai S, Kunos G, (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
22. Islam T, Asplund A, Lindvall J, Nygren L, Liden J, et al. (2003) High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of cyclin D1 in mantle cell lymphoma. Leukemia 17: 1880-1890.
23. Wang D, Wang H, Ning W, Backlund M, Dey S, et al. (2008) Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476.
24. Gustafsson SB, Palmqvist R, Henriksson ML, Dahlin AM, Edin S, et al. (2011) High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 6: e23003.
25. Xu X, Liu Y, Huang S, Liu G, Xie C, et al. (2006) Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Gen Cytogen 171: 31-38.
26. Michalski C, Oti F, Erkan M, Sauliunaite D, Bergmann F, et al. (2008) Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122: 742-750.
27. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, et al. (2009) A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174-182.
28. Czifra G, Varga A, Nyeste K, Marincsák R, Tóth B, et al. (2009) Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol 135: 507-514.
29. Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, et al. (2010) Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One 5: e12275.
30. Cudaback E, Marrs W, Moeller T, Stella N, (2010) The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS ONE 5: e8702.
31. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikström P, et al. (2010) Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 16: 1245-1255.
32. Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, et al. (2012) Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 7: e47994.
33. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P, (2002) Prognostic value of the Gleason score in prostate cancer. BJU International 89: 538-542.
34. Josefsson A, Wikström P, Granfors T, Karlberg L, et al. (2012) Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol 46: 247-257.
35. R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
36. Mimeault M, Batra SK, (2011) Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med 17: 949-964.
37. Le Page C, Koumakpayi IH, Péant B, Delvoye N, Saad F, et al. (2012) ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells. Prostate 72: 777-788.
38. Lehmann R, (1977) General derivation of partial and multiple rank correlation coefficients. Biom J 19: 229-236.
39. Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M, (2013) The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 34: 273-282.
40. Hart S, Fischer O, Ullrich A, (2004) Cannabinoids induce cancer cell proliferation via tumor necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor. Cancer Res 64: 1943-1950.
41. Sarnatoro D, Pisanti S, Santoro A, Gazzerro P, Malfitano A, et al. (2006) The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 70: 1298-1306.
42. Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, et al. (2009) Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer 125: 996-1003.
43. Ayala G, Thompson T, Yang G, Frolov A, Li R, et al. (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10: 6572-6578.
44. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171.
45. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, et al. (2005) Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119-134.
46. Le Page C, Koumakpayi IH, Alam-Fahmy M, Mes-Masson A-M, Saad F, (2006) Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer 94: 1906-1912.
47. del Peso L, González-García M, Page C, Herrera R, Nuñez G, (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
48. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, et al. (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505.
49. Gómez del Pulgar T, Velasco G, Guzmán M, (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347: 369-373.
50. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236.
51. McCall P, Gemmell LK, Mukherjee R, Bartlett JMS, Edwards J, (2008) Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 98: 1094-1101.